Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain
Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future sarbecovirus-induced disease. However, most mAbs isolated so far neutralize only a few sarbecovirus strains. Therefore, there is...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_1fbcc6e3d1d94ac096e091f76a23bb0a | ||
042 | |a dc | ||
100 | 1 | 0 | |a Denise Guerra |e author |
700 | 1 | 0 | |a Laura Radić |e author |
700 | 1 | 0 | |a Mitch Brinkkemper |e author |
700 | 1 | 0 | |a Meliawati Poniman |e author |
700 | 1 | 0 | |a Lara van der Maas |e author |
700 | 1 | 0 | |a Jonathan L. Torres |e author |
700 | 1 | 0 | |a Andrew B. Ward |e author |
700 | 1 | 0 | |a Kwinten Sliepen |e author |
700 | 1 | 0 | |a Janke Schinkel |e author |
700 | 1 | 0 | |a Rogier W. Sanders |e author |
700 | 1 | 0 | |a Marit J. van Gils |e author |
700 | 1 | 0 | |a Tim Beaumont |e author |
245 | 0 | 0 | |a Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain |
260 | |b Taylor & Francis Group, |c 2024-12-01T00:00:00Z. | ||
500 | |a 10.1080/21645515.2024.2388344 | ||
500 | |a 2164-554X | ||
500 | |a 2164-5515 | ||
520 | |a Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future sarbecovirus-induced disease. However, most mAbs isolated so far neutralize only a few sarbecovirus strains. Therefore, there is a growing interest in bispecific antibodies (bsAbs) which can simultaneously target different spike epitopes and thereby increase neutralizing breadth and prevent viral escape. Here, we generate and characterize a panel of 30 novel broadly reactive bsAbs using an efficient controlled Fab-arm exchange protocol. We specifically combine some of the broadest mAbs described so far, which target conserved epitopes on the receptor binding domain (RBD). Several bsAbs show superior cross-binding and neutralization compared to the parental mAbs and cocktails against sarbecoviruses from diverse clades, including recent SARS-CoV-2 variants. BsAbs which include mAb COVA2-02 are among the most potent and broad combinations. As a result, we study the unknown epitope of COVA2-02 and show that this mAb targets a distinct conserved region at the base of the RBD, which could be of interest when designing next-generation bsAb constructs to contribute to a better pandemic preparedness. | ||
546 | |a EN | ||
690 | |a SARS-CoV-2 | ||
690 | |a variants | ||
690 | |a sarbecoviruses | ||
690 | |a bispecific antibodies | ||
690 | |a cross-reactivity | ||
690 | |a breadth | ||
690 | |a Immunologic diseases. Allergy | ||
690 | |a RC581-607 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) | |
787 | 0 | |n https://www.tandfonline.com/doi/10.1080/21645515.2024.2388344 | |
787 | 0 | |n https://doaj.org/toc/2164-5515 | |
787 | 0 | |n https://doaj.org/toc/2164-554X | |
856 | 4 | 1 | |u https://doaj.org/article/1fbcc6e3d1d94ac096e091f76a23bb0a |z Connect to this object online. |